CLINICAL NUCLEAR MEDICINE, cilt.41, sa.7, ss.561-563, 2016 (SCI-Expanded, Scopus)
Everolimus is a mammalian target of rapamycin inhibitor that has been recently approved for the treatment of patients with advanced progressive pancreatic neuroendocrine tumor. Here, we present a case in which an early therapy response to everolimus was effectively demonstrated by Ga-68-DOTATATE PET/CT.